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CARDIOVASCULAR MEDICINE
Prevalence of myocardial viability assessed by single
photon emission computed tomography in patients with
chronic ischaemic left ventricular dysfunction
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Objective: To assess the prevalence of myocardial viability by technetium-99m (Tc-99m)-tetrofosmin/
fluorine-18-fluorodeoxyglucose (FDG) single photon emission computed tomography (SPECT) in
patients with ischaemic cardiomyopathy.
Design: A retrospective observational study.
Setting: Thoraxcenter Rotterdam (a tertiary referral centre).
Patients: 104 patients with chronic coronary artery disease and severely depressed left ventricular
function presenting with heart failure symptoms.
Main outcome measures: Prevalence of myocardial viability as evaluated by Tc-99m-tetrofosmin/
FDG SPECT imaging. Two strategies for assessing viability in dysfunctional myocardium were used:
perfusion imaging alone, and the combination of perfusion and metabolic imaging.
Results: On perfusion imaging alone, 56 patients (54%) had a significant amount of viable myocar-
dium, whereas 48 patients (46%) did not. Among the 48 patients with no significant viability by per-
fusion imaging alone, seven additional patients (15%) had significantly viable myocardium on
combined perfusion and metabolic imaging. Thus with a combination of perfusion and metabolic
imaging, 63 patients (61%) had viable myocardium and 41 (39%) did not.
Conclusions: On the basis of the presence of viable dysfunctional myocardium, 61% of patients with
chronic coronary artery disease and depressed left ventricular ejection fraction presenting with heart
failure symptoms may be considered for coronary revascularisation. The combination of perfusion and
metabolic imaging identified more patients with significant viability than myocardial perfusion imaging
alone.
Chronic coronary artery disease is the most importantcause of left ventricular dysfunction leading to heartfailure. When this occurs it has an extremely poor
prognosis.1 2 In nearly 70% of the patients in 13 major heart
failure trials, coronary artery disease was the underlying cause
of the heart failure.3 The management of these patients
remains difficult, while both the incidence and the prevalence
of chronic heart failure have been increasing in recent years.4
Medical treatment is still suboptimal in these patients,
although significant improvements in survival have been
achieved with angiotensin converting enzyme (ACE) inhibi-
tion, blockade of aldosterone receptors by spironolactone, and
β adrenergic blockade.5–7 Other therapeutic options are heart
transplantation and coronary revascularisation. The possibili-
ties of heart transplantation are limited by the availability of
donor hearts, but coronary revascularisation could be an
effective alternative. In a subset of patients with heart failure
secondary to chronic coronary artery disease, revascularisa-
tion has been shown to improve left ventricular ejection frac-
tion (LVEF), heart failure symptoms, and survival.8 9 However,
revascularisation in such patients is also associated with
increased periprocedural morbidity and mortality.8 9
The concept of myocardial viability was proposed to explain
the improvement of LVEF and heart failure symptoms after
revascularisation.10 11 Dysfunctional but viable myocardium is
likely to regain contractile function after coronary
revascularisation.12 On the other hand, dysfunctional non-
viable myocardium (scar tissue) clearly will not improve.
Bonow estimated that between 25–40% of patients with heart
failure caused by ischaemic heart disease have the potential
for functional improvement after revascularisation.13 Quantifi-
cation of myocardial viability in patients with chronic
coronary artery disease, depressed left ventricular function,
and heart failure is at present limited, but this information is
important as such patients may benefit from
revascularisation.14 15 Our aim in this study was therefore to
evaluate myocardial viability in a consecutive series of 104
patients with chronic coronary artery disease and depressed
LVEF presenting with heart failure symptoms.
METHODS
Patient population, study protocol
The study population consisted of 104 consecutive patients
with ischaemic cardiomyopathy (chronic coronary artery dis-
ease as assessed by angiography and an LVEF of < 35%), who
presented with heart failure as the predominant symptom and
were referred for evaluation of myocardial viability. Patients
with primary cardiomyopathy or concomitant significant val-
var disease were not included.
All patients underwent resting echocardiography to identify
dysfunctional myocardial tissue, and dual isotope simultane-
ous acquisition myocardial single photon emission computed
tomography (SPECT), including Tc-99m tetrofosmin and
fluorodeoxyglucose (FDG) to assess myocardial perfusion and
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glucose utilisation, respectively.16 17 LVEF was assessed by
radionuclide ventriculography.
The local medical ethics committee approved the protocol
and all patients gave informed consent.
Assessment of contractile function
A Hewlett-Packard Sonos-5500 imaging system (Hewlett-
Packard Inc, Andover, Massachusetts, USA), equipped with a
1.8 MHz transducer using second harmonic imaging to
optimise endocardial border visualisation, was used to record
cross sectional echocardiograms. Four standard views (apical
two and four chamber views, and parasternal short and long
axis views) were stored on tape.
Off-line interpretation was undertaken using a computer
system that digitised the taped images and displayed them in
a cineloop format. Two experienced reviewers blinded to the
SPECT data scored the digitised echocardiograms visually. In
case of disagreement, a majority decision was achieved by a
third reviewer. The left ventricle was divided according to the
standard 16 segment model described by the American Soci-
ety of Echocardiography (six basal, six distal, and four apical
segments).18 Regional wall motion and systolic wall thicken-
ing were scored using a five point grading scale: 1, normal
(normal endocardial excursion and systolic wall thickening);
2, mildly hypokinetic (mildly reduced excursion and wall
thickening); 3, severely hypokinetic (severely reduced excur-
sion and thickening); 4, akinetic (absent excursion and wall
thickening); 5, dyskinetic (paradoxical systolic outward wall
motion). Myocardial segments were considered normal if the
regional wall motion was normal or mildly hypokinetic. Only
segments with severe hypokinesia, akinesia, or dyskinesia
were evaluated for myocardial viability.
SPECT data acquisition
After a light breakfast, the patients received an intravenous
injection of Tc-99m-tetrofosmin (600 MBq) to evaluate
resting perfusion. FDG imaging to evaluate glucose utilisation
was done after the administration of acipimox (500 mg oral
dose) in all patients. Acipimox enhances myocardial FDG
uptake by reducing the plasma concentration of free fatty
acids. Following acipimox administration, the patients re-
ceived a low fat, carbohydrate rich meal. This small meal fur-
ther enhances myocardial FDG uptake by stimulating endog-
enous insulin release. Several studies have shown excellent
imaging using acipimox.19
Patients with diabetes mellitus were asked to continue their
antidiabetic drug regimen. Plasma glucose concentrations
were measured immediately before the study. In patients with
a plasma glucose concentration of more than 8 mmol/l, insu-
lin was given intravenously to enhance myocardial FDG
uptake. The plasma glucose concentration was then measured
again and additional intravenous insulin given if necessary.
Sixty minutes after the meal, FDG (185 MBq) was injected,
and after an a further 45minutes to allow cardiac FDG uptake,
dual isotope simultaneous acquisition SPECT was performed.
Perfusion and metabolic imaging were both done at rest with-
out stressors. Patients continued their normal cardiac drug
treatment during the SPECT study.
A triple head gamma camera system (Picker Prism 3000XP,
Cleveland, Ohio, USA) was used. The camera system was
equipped with high energy 511 keV collimators. The energies
were centred on the 140 keV photon peak of technetium-99m
tetrofosmin with a 15% window and on the 511 keV photon
peak of FDGwith a 15%window.Data acquisition was done in
the supine position, over 360° (120 sectors of 3°). Total imag-
ing time was 32 minutes. Data were stored in a 64 × 64, 16 bit
matrix.
SPECT data reconstruction and analysis
From the raw scintigraphic data, 6 mm thick (1 pixel) transax-
ial slices were reconstructed by filtered back projection using a
Butterworth filter (cut off frequency at 0.17 cycle/pixel of order
3.5). Attenuation correction was not applied. Further recon-
struction yielded standard short and long axis projections
perpendicular to the heart axis. The Tc-99m-tetrofosmin and
the FDG data were reconstructed simultaneously. This approach
permits exact alignment of the perfusion and FDG images.
The perfusion and FDG short axis slices were adjusted to
peak myocardial activity (100%). The left ventricle was divided
into 16 segments matching the echocardiographic segments.20
Both Tc-99m-tetrofosmin and FDG uptake defects were graded
semiquantitatively on a four point scale: 0, normal (> 75%–
100%); 1, mildly reduced (> 50%–75%; 2, moderately reduced
(> 25%–50%); 3, severely reduced or absent (< 25% uptake).
Dysfunctional segments (identified by resting echocardio-
graphy) were subsequently evaluated for viability.
Viable myocardium was defined using two approaches: per-
fusion criteria alone, and a combination of perfusion and
metabolic criteria. Using perfusion alone, myocardium with a
To-99m-tetrofosmin uptake score of < 1 was considered
viable, while myocardium with a score of > 2 was considered
non-viable. Using the combination of perfusion and metabo-
lism, myocardium with a Tc-99m-tetrofosmin uptake score of
< 1 or with a reduction in Tc-99m-tetrofosmin uptake score
that was more severe than the reduction in FDG activity by
> 1 point (perfusion–metabolism mismatch pattern) was
considered viable. Dysfunctional myocardium with a propor-
tionate reduction in both Tc-99m-tetrofosmin and FDG
uptake (perfusion–metabolism match pattern) was consid-
ered non-viable.
A patient with four or more dysfunctional but viable
segments was considered to have a functionally significant
amount of viable myocardium. This definition is based on previ-
ous work using receiver operating characteristic (ROC) curve
analysis showing that improvement in LVEF after revascularisa-
tion can be anticipated when more than 25% of the left ventri-
cle is viable (four or more segments in a 16 segment model).21
Assessment of LVEF
To assess LVEF at the time of the viability testing, we
performed radionuclide ventriculography at rest in all
patients. A small field of view gamma camera system (Orbiter,
Siemens, Erlangen, Germany) was used, oriented in a 45° left
anterior oblique position with a 5–10° caudal tilt. After injec-
tion of To-99m (740 MBq), radionuclide ventriculography was
Table 1 Clinical characteristics of
104 patients undergoing dual isotope
simultaneous acquisition single photon
emission computed tomography
Clinical features
Number of
patients
LVEF <20% 23 (22%)
LVEF >20%, <30% 54 (52%)
LVEF >30%, <35% 27 (26%)
Number of stenosed arteries
(mean (SD))
2.1 (0.8)
Previous MI 97 (93%)
Previous CABG 16 (15%)
Previous PTCA 13 (13%)
Diabetes mellitus 15 (14%)
Drug treatment
ACE inhibitors 86 (83%)
β Blockers 53 (51%)
Calcium antagonists 29 (28%)
Nitrates 74 (71%)
Diuretics 66 (63%)
Data are n (%) unless specified.
ACE, angiotensin converting enzyme; CABG,
coronary artery bypass graft surgery; LVEF, left
ventricular ejection fraction; MI, myocardial
infarction; PTCA, percutaneous transluminal
coronary angioplasty.
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done at rest with the patient in the supine position. The LVEF
was calculated by standard methods (Odyssey VP, Picker,
Cleveland, Ohio, USA).
Statistical analysis
All continuous data are expressed as mean (SD). Percentages
are rounded. Comparisons were made using the Student t test
for unpaired samples. A probability value of p < 0.05 was
considered significant.
RESULTS
Patient characteristics
Clinical characteristics of the 104 patients (87 men, 17
women;mean (SD) age, 60 (9) years) are summarised in table
1. All patients presented with symptoms of heart failure. The
mean New York Heart Association (NYHA) functional class
was 2.5 (0.9); 67 patients were in NYHA class III or IV. The
majority (93%) of the patients had suffered a previous
myocardial infarct (all occurring more than one month before
viability assessment). LVEF assessed by radionuclide ventricu-
lography averaged 25 (7)% (range 9–35%). In 23 patients the
LVEF was 20% or less, in 54 it was between 21% and 30%, and
in 27 it was more than 30%.
Segmental analysis
Contractile function
Cross sectional echocardiographic analysis of regional left
ventricular function was done in 1664 segments, of which 189
were normal and 297 mild hypokinetic. Of 1178 dysfunctional
segments (71%), 584 showed severe hypokinesia, 578 aki-
nesia, and 16 dyskinesia. The mean (SD) number of dysfunc-
tional segments per patient was 11.3 (4.2).
Perfusion imaging alone
Using myocardial perfusion as the only criterion of viability,
497 dysfunctional segments (42%) were classified as viable.
Three hundred and sixteen dysfunctional segments (27%) had
normal Tc-99m-tetrofosmin uptake, and 181 (15%) had a
mildly reduced uptake. The remaining 681 dysfunctional seg-
ments (58%) had a Tc-99m tetrofosmin uptake score of 2 or 3
and were classified as non-viable.
Combined perfusion and metabolic imaging
Using perfusion imaging in conjunction with FDG SPECT, 558
of the dysfunctional myocardial segments (47%) were
classified as viable. Of these viable dysfunctional segments,
Figure 1 Myocardial perfusion in viable and non-viable tissue. In
viable myocardium, perfusion was normal in 57% of dysfunctional
segments, mildly reduced in 32%, moderately reduced in 10%, and
severely reduced or absent in 1%. Non-viable tissue had moderately
reduced perfusion in 42% of dysfunctional segments and severely
reduced or absent perfusion in 58%.
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Table 2 Comparison of segment viability in three
groups divided by left ventricular ejection fraction
Characteristics of
segments
LVEF <20%
(23 patients)
LVEF 21–30%
(54 patients)
LVEF >30%
(27 patients)
Dysfunctional 14.1 (2.0) 10.9 (4.5)† 9.7 (3.9)
Viable by Tc-99m 6.4 (3.7) 4.6 (3.8)* 3.8 (3.2)
Viable by Tc-99m
+ FDG
7.2 (4.0) 5.1 (4.1)* 4.2 (3.2)
*p<0.05; †p<0.005 v LVEF <20%.
FDG, fluorodeoxyglucose; LVEF, left ventricular ejection fraction.
Figure 2 (A) Amount of viable myocardium indicated by the
number of viable segments in 23 patients with a left ventricular
ejection fraction (LVEF) < 20%. Using perfusion as the only criterion
of viability, 18 patients (78%) had significant viability (> 4 viable
segments) and five (22%) did not have significant viability.
(B) Amount of viable myocardium indicated by the number of viable
segments in 54 patients with an LVEF > 20% but < 30%. Using
perfusion as the only criterion of viability, 27 patients (50%) had
significant viability (> 4 viable segments), and 27 (50%) did not
have significant viability. (C) Amount of viable myocardium
indicated by the number of viable segments in 27 patients with an
LVEF > 30% but < 35%. Using perfusion as the only criterion of
viability, 11 patients (41%) had significant viability (> 4 viable
segments) and 16 (59%) did not have significant viability.
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497 (42%) had normal or mildly reduced perfusion and 61
additional segments (5%) had a perfusion–metabolism
mismatch pattern. Conversely, 620 dysfunctional segments
(53%) were classified as non-viable (with a matching pattern
of perfusion and metabolism). Figure 1 shows the myocardial
perfusion in the dysfunctional segments that were classified
as viable and non-viable by combined perfusion andmetabolic
imaging.
Patient analysis
Contractile function
Patients with an LVEF of 20% or less had more dysfunctional
segments than those with an LVEF of 21–30% (14.1 (2.0) v
10.9 (4.5), p < 0.005) or those with an LVEF of more than 30%
(14.1 (2.0) v 9.7 (3.9), p < 0.0001). The number of dysfunc-
tional segments was not significantly different between
patients with an LVEF of more than 30% and those with an
LVEF of 21–30% (9.7 (3.9) v 10.9 (4.5); p = 0.2) (table 2).
Perfusion imaging alone
All patients had on average 4.8 (3.7) (range 0–14) dysfunc-
tional but viable segments. When myocardial perfusion was
used as the only criterion of viability, 56 patients (54%) had a
significant amount of viable myocardium (on average 7.5 (2.9)
segments) and 48 patients (46%) did not have significant
viability (1.6 (1.2) segments). Figure 2 shows the number of
viable segments per patient with perfusion imaging alone for
the three LVEF groups.
Combined perfusion and metabolic imaging
Among the 48 patients with no significant viability by
perfusion imaging alone, seven additional patients (15%) had
viable myocardium when assessed using a combination of
perfusion and metabolic imaging. All 56 patients with signifi-
cant viability when assessed by perfusion alone also had
significant viability with combined perfusion and metabolic
imaging (on average, 8.2 (3.2) viable segments). Thus
perfusion imaging in combination with metabolic imaging
showed that 63 patients (61%) had a significant amount of
viable tissue (7.8 (3.2) segments). Forty one patients (39%)
did not have significant residual viable dysfunctional tissue
(on average, 1.6 (1.2) viable segments). Overall, the patients
had 5.4 (4.0) viable dysfunctional segments. Figure 3 shows
the number of viable dysfunctional segments for patients in
the three different LVEF categories.
DISCUSSION
Viable myocardium
Heart failure is becoming a major problem in clinical cardiol-
ogy. In recent years the incidence of patients with heart failure
has increased despite progress in prevention and treatment.4
Chronic heart failure is predominantly caused by coronary
artery disease and has a poor prognosis.3 In a subset of
patients with heart failure resulting from coronary artery dis-
ease, coronary revascularisation may improve left ventricular
function, heart failure symptoms, and survival,8 9 but the risks
of revascularisation in such patients are substantial. Also,
apart from the need to assess clinical variables such as target
vessels and comorbid factors, it is important to evaluate myo-
cardial viability as part of the complex selection process in
candidates for revascularisation.
Previous estimates suggest that between 25–40% of the
patients with heart failure caused by coronary artery disease
may show useful functional improvement after
revascularisation.13 In our hospital, patients with coronary
artery disease, a depressed LVEF, and heart failure are always
referred for assessment of myocardial viability. This approach
allows improved risk stratification and results in optimal
treatment for the individual patient. In the present study, we
examined myocardial viability in a consecutive series of
patients from our heart failure registry.
A few previous studies have examined myocardial viability
on an individual patient basis. Using FDG positron emission
tomography (PET), Pasquet and colleagues found that among
66 patients with severe left ventricular dysfunction, 28 (47%)
had an improvement in LVEF of at least 5% after coronary
revascularisation, while eight (14%) had an improvement of
more than 10%.22 Al-Mohammad and colleagues studied the
prevalence of hibernating myocardium in 27 patients using
FDG PET.14 Fourteen of these had significant areas of
hibernating myocardium on PET. Auerbach and associates,
also using FDG PET, studied 283 patients with ischaemic car-
diomyopathy and found that 156 (55%) had viable
myocardium.15 In the present study, 54% of the patients
showed significant viability when myocardial perfusion was
Figure 3 (A) Amount of viable myocardium indicated by the
number of viable segments in 23 patients with a left ventricular
ejection fraction (LVEF) < 20%. Using perfusion in combination with
metabolic criteria for viability, 19 patients (83%) had significant
viability (> 4 viable segments) and four (17%) did not. (B) Amount of
viable myocardium indicated by the number of viable segments in
54 patients with an LVEF > 20% but < 30%. Using perfusion in
combination with metabolic criteria for viability, 30 patients (56%)
had significant viability (> 4 viable segments) and 24 (44%) did not.
(C) Amount of viable myocardium indicated by the number of viable
segments in 27 patients an LVEF > 30% but < 35%. Using perfusion
in combination with metabolic criteria for viability, 14 patients (52%)
had significant viability (> 4 viable segments) and 13 (48%) did not.
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used as the only index, while perfusion imaging in combina-
tion with metabolic imaging identified a further 7%; thus 61%
of the patients in all had a significant amount of viable tissue.
These observations are in close agreement with those of
Al-Mohammad and Auerbach using FDG PET.14 15
In the present study patients with an LVEF of 20% or less
had more dysfunctional but viable segments than those with
an LVEF of 21–30% or with an LVEF of more than 30%. In line
with our results, Fath-Ordoubadi and colleagues reported that
in 47 patients with coronary artery disease and chronic left
ventricular dysfunction, those with an LVEF of 30% or less had
more dysfunctional but viable segments than those with an
LVEF of more than 30%.23 Moreover, after revascularisation the
LVEF improved in patients with an initial LVEF of 30% or less,
whereas it remained unchanged in those with an LVEF of
more than 30%. It seems that patients with the most severe
left ventricular dysfunction benefit more from revascularisa-
tion than those with less severe dysfunction. These findings
may have important clinical implications in relation to revas-
cularisation, as severe left ventricular dysfunction has a very
poor prognosis when treated medically.3
How much viable tissue is required to be clinically
relevant?
In the present study a patient was considered to have a
significant amount of viable myocardium if there were at least
four or more dysfunctional viable segments in a 16 segment
model. This definition was based on a previous study using
ROC curve analysis showing that improvement in LVEF after
revascularisation can be anticipated when 25% or more of the
left ventricle is viable.21 Di Carli and colleagues reported that in
patients with coronary artery disease and left ventricular dys-
function andwithmore than 5% viable tissue, the survival rate
of revascularised patients was higher than in those who were
treated medically (88% v 50%).24 These data suggest that
revascularisation in patients with 5–25% of viable myocardial
tissue, while being unlikely to result in functional recovery,
may still improve prognosis. Moreover, five prognostic FDG
PET studies have reported a high event rate (42%) in patients
with viable tissue treated medically,25 though these studies
were of retrospective design without randomised treatment.
Nevertheless it appears that for functional improvement to
occur more viable myocardium is needed than for improve-
ment in prognosis. Howmuch viable myocardium is needed to
be clinically relevant remains to be established in randomised
prospective studies focusing on both functional improvement
and prognosis.
Perfusion alone versus perfusion and metabolism
Detection of reduced myocardial perfusion (without any addi-
tional information about metabolism) has been proposed as a
method for differentiating viable from non-viable myocar-
dium. Thallium-201 or technetium-99m labelled tracers have
been used in various studies to assess myocardial viability.26
However, it appears that the diagnostic accuracy of perfusion
imaging for detecting viable tissue is less than that of
perfusion imaging combined with FDG metabolic imaging.
Three studies have shown that metabolic evidence of viability
may be present while perfusion is absent. Sawada and
colleagues studied 20 patients with a previous myocardial inf-
arction and reported that evidence of viability obtained by
FDG PET was still present in 50% of segments which had
technetium-99m activity of less than 40%.27 Soufer and asso-
ciates, in a study of 37 patients with coronary artery disease,
found that FDG PET accurately predicted functional improve-
ment after revascularisation in segments that were non-viable
with technetium-99m imaging but viable with FDGmetabolic
imaging.28 Altehoefer and colleagues studied 111 patients with
coronary artery disease and showed that 5–11% of segments
with technetium-99m activity of 30% or less were viable
according to FDG imaging.29
Our study supports those findings. When only perfusion
was used to indicate viable myocardium, 56 patients (54%)
showed significant viability, while a combination of perfusion
and FDG imaging identified 63 patients (61%) with signifi-
cantly viable myocardium. Hence, of the 48 patients with no
significant viability by perfusion imaging alone, seven
additional patients (15%) had significantly viable myocardium
when the information on metabolic imaging was added. This
is of clinical relevance, as about one in seven patients initially
thought not to have a significant amount of viable tissue on
perfusion imaging were found to be eligible for revascularisa-
tion when the combined test was used. It thus appears that
perfusion imaging alone underestimates viability, and the
combination of perfusion imaging and FDG metabolic
imaging is a better way of discriminating between viable and
non-viable myocardium. Furthermore, combined imaging has
been shown to provide better discrimination between seg-
ments with a relatively high and a relatively low likelihood of
recovery of function after revascularisation.30
Study limitations
The centre where this study took place is a tertiary referral
centre and thus a pre-existing patient selection bias may be
present.
The SPECT imaging protocol did not include administration
of nitrates before tracer injection. Nitrate administration may
enhance the detection of myocardial viability with To-99m-
tetrofosmin SPECT in patients with coronary artery disease
and left ventricular dysfunction.31
During SPECT data reconstruction, no attenuation correc-
tion was applied and this may have influenced the accuracy of
the results. Matsunari and colleagues reported that the use of
attenuation corrected Tc-99m-tetrofosmin SPECT improved
the detection of viable myocardium, mainly by decreasing the
underestimation of viability in the inferior septal region.32
The findings in our study did not include the results of
recovery of function after revascularisation. However, that was
not a goal of the study.Our aimwas specifically to quantify the
presence of significant myocardial viability in patients with
chronic coronary artery disease, depressed LVEF, and heart
failure symptoms.
Conclusions
On the basis of the presence of viable dysfunctional
myocardium, 61% of patients with chronic coronary artery
disease and a depressed left ventricular ejection fraction
presenting with heart failure symptomsmay be considered for
coronary revascularisation. The combination of perfusion and
metabolic imaging identified more patients with viable
myocardium than perfusion imaging alone.
. . . . . . . . . . . . . . . . . . . . .
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Spontaneous right coronary artery dissection
A44 year old woman presented with aneight month history of recurrent exer-tional chest and back pain.A diagnosis of
Marfan syndrome had been made in 1985; in
1988, following the discovery of a chronic type
A dissection, she underwent a Starr Edwards
aortic valve and ascending aortic replacement
with reimplantation of the coronary arteries.
On this presentation magnetic resonance
scanning showed a dissection flap extending
across the aortic arch that had been present
and stable for 13 years. Myocardial perfusion
scanning demonstrated a reduction in tracer
uptake in the inferior wall. Coronary angio-
graphy revealed a spontaneous distal right
coronary artery (RCA) dissection in a tortu-
ous vessel (panel A, black arrow). The RCA
was cannulated using a 6 French Judkins
right guide catheter and two guide wires.
Direct stenting of the lesion was performed
uneventfully with a 3.5 × 23 Sonic stent
(Cordis) (panel B,white arrow). Following the
procedure the patient remains well.
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